AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04449328 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computerized Mirror Therapy (CMT)
Description: Computerized Mirror Therapy (CMT) will be realizing by the device Intensive Visual Simulation 3 (IVS3).~The patient looks on a screen in front of him, mirroring the movements made by his hand, while attempting to perform the same movement with his other hand.
Study NCT04449328 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Computerized Mirror Therapy (CMT)
Description: Computerized Mirror Therapy (CMT) will be realizing by the device Intensive Visual Simulation 3 (IVS3).~The patient looks on a screen in front of him, mirroring the movements made by his hand, while attempting to perform the same movement with his other hand.
Study NCT04449328 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tendon vibration
Description: Transcutaneous vibrations are used. This device allows vibrations from 50 to 120 Hz with amplitude of 1 mm. This study the frequency used is 70 and 80 Hz.
Study NCT04449328 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Tendon vibration
Description: Transcutaneous vibrations are used. This device allows vibrations from 50 to 120 Hz with amplitude of 1 mm. This study the frequency used is 70 and 80 Hz.
Study NCT04613232 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable sensor
Description: The patients will be asked to wear an Apple Watch during their treatment course. The watch will pasively collect sensor data (heart rate and physical activity)
Study NCT04734652 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Biktarvy®
Description: Biktarvy® is a fixed dose combination, single tablet containing bictegravir (BIC), emtricitabine (FTC), and tenofovir alafenamide (TAF) for oral administration.~BIC is an integrase strand transfer inhibitor (INSTI). FTC, a synthetic nucleoside analog of cytidine, is an HIV nucleoside analog reverse transcriptase inhibitor (HIV NRTI). TAF, an HIV NRTI, is converted in vivo to tenofovir, an acyclic nucleoside phosphonate (nucleotide) analog of adenosine 5'-monophosphate. Each tablet contains 50 mg of BIC (equivalent to 52.5 mg of bictegravir sodium), 200 mg of FTC, and 25 mg of TAF (equivalent to 28 mg of tenofovir alafenamide fumarate) and the following inactive ingredients: croscarmellose sodium, magnesium stearate, and microcrystalline cellulose.
Study NCT04734652 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: TLD- fixed-drug combination single tablet
Description: Standard of care Dolutegravir-based regimen
Study NCT05870839 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VXCO-100
Description: Sterile liquid for injection
Study NCT05154981 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education communication skills (ECS) training
Description: Education communication skills (ECS) training videos were developed from LEAPS (Listen, Educate, Assess, Partner and Support), a set of 10- to 20- sec videos that help patients and physicians communicate health concerns and treatment plans to each other. ECS training videos target parent-teacher communication during the transition to school for children with autism.
Study NCT05402956 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Moderate aerobic exercise training
Study NCT06472947 — intervention group
Intervention type: DEVICE
Intervention: ULM and MSOT
Description: transplanted kidney will be examined non-invasively with ULM and MSOT
Study NCT06122350 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Earthquake preparedness training
Description: Mothers with physically disabled children will be trained on what to do before, during and after an earthquake within the scope of earthquake preparedness training.
Study NCT06542367 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tympanoplasty performed under local anesthesia using fat graft and Tachosil.
Description: Under local anesthesia, subcutaneous fat from the neck will be harvested. After that trimming of the perforation edges, planting the fat graft medial to the tympanic membrane and placement of the Tachosil on top of the fat graft.~gelfoam is placed lateral to the tympanic membrane to fill the ear canal. follow-up will be held at 2, 4-6 and 12 months following the procedure, with audiometric and otological evaluation
Study NCT05232552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib hydrochloride
Description: anlotinib was administered orally 12mg daily for 14 days concurrent with inductive chemotherapy (TP ) for 3 cycles and definitive chemoradiation for additional 2 cycles
Study NCT05232552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: induction chemotherapy
Description: docetaxel 75mg/m2 d1 plus DDP 75mg/m2 d1 for 3 cycles every 21days
Study NCT05232552 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: concurrent chemoradiation
Description: definitive IMRT (GTV>66Gy) concurrent with 2 cycles of DDP (100mg/m2 d1) and anlotinib (12mg d1-14) every 21 days
Study NCT04752371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camoteskimab (CERC-007, AVTX-007, AEVI-007)
Description: Intravenous (IV) Infusion
Study NCT05154981 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partners in School
Description: Partners in School is a problem-solving consultation that encourages parents and teachers to implement the same evidence-based interventions across home and school
Study NCT05154981 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Partners in School
Description: Partners in School is a problem-solving consultation that encourages parents and teachers to implement the same evidence-based interventions across home and school
Study NCT05141500 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STRYKER SUSTAINABILITY SOLUTIONS PULSE OXIMETERS
Description: Reprocessed noninvasive pulse oximeters~* 1859 \& 2329~* MAX-A \& MAX-N
Study NCT05107128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-718
Description: Oral capsules.
Study NCT05107128 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SAGE-718-matching oral capsules.
Study NCT06380296 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Primary molars pulpotomies with NeoMTA
Description: Primary molar pulpotomies will be performed by trained dentists using NeoMTA, a bioactive material containing calcium silicate known for its bio-active and bone forming potential. Follow-up visits at 1, 6, 12 and 24 months will be conducted to assess success rate, and clinical and radiographic outcomes
Study NCT06380296 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Primary molar pulpotomies with NeoPUTTY
Description: Primary molar pulpotomies will be performed by trained dentists using NeoPUTTY, a ready to use bioactive material containing calcium silicate. Follow-up visits at 1, 6, 12 and 24 months will be conducted to assess success rate, and clinical and radiographic outcomes
Study NCT04744545 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Meru Health Program
Description: 12 week evidence-based mental health intervention overseen by a licensed clinical therapist delivered via Smartphone app
Study NCT04744545 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meru Health Program
Description: 12 week evidence-based mental health intervention overseen by a licensed clinical therapist delivered via Smartphone app
Study NCT04744545 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: 1500mg/day curcumin plus black pepper to aid absorption
Study NCT05676229 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic blend
Description: Lactobacillus gasseri CCT 7850 and Bifidobacterium lactis CCT 7858
Study NCT05676229 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin only (vehicle)
Study NCT05508373 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JS019
Description: Four dose levels are preset: 0.3 mg/kg, 1 mg/kg, 3 mg/kg, and 10 mg/kg. The subjects are treated with JS019 by intravenous infusion, once every 3 weeks (Q3W). A treatment cycle is 21 days, and the DLT observation period is 21 days after the first administration.
Study NCT05648799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP30341 capsules 200 mg
Description: orall take of capsules twice a day
Study NCT05648799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy
Description: Standard medicines for treatment of a new coronavirus infection 2019 (COVID-19).
Study NCT05401006 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acitretin 25Mg Cap
Description: Acitretin is an oral retinoid (a derivative of vitamin A) given in a dose 0.25-1 mg /kg/day for 3months in psoriatic patients
Study NCT05401006 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Narrowband ultraviolet B
Description: Narrowband UVB is the most common form of phototherapy used to treat psoriasis, given 2-3 sessions per week for 3 successive months
Study NCT04903392 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Backward Walking Training
Description: The training speed will start at the basic walking speed and will increase by 5% of the starting speed each week. The training, which will take 30 minutes, will be as follows: 5 minutes forward walking (warm-up phase), 20 minutes backward walking (intervention phase) and 5 minutes forward (cooling phase).~-three times a week for six weeks
Study NCT04903392 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Forward Walking Training
Description: The training speed will start at the basic walking speed and will increase by 5% of the starting speed each week. It will be in the form of walking forward for 30 minutes.~-three times a week for six weeks
Study NCT05310422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivanisiran sodium ophthalmic solution
Description: 1 drop in the affected eye(s) once daily
Study NCT05310422 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle ophthalmic solution
Description: 1 drop in the affected eye(s) once daily
Study NCT06395818 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prefabricated CAD-CAM allogeneic bone block hydrated using hyaluronic acid
Description: exposure of atrophic posterior mandibular ridge, augmentation with CAD-CAM prefabricated allogenic bone block which fixed with titanium screws ,The block was coated with a nonporous d-PTFE membrane
Study NCT06395818 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prefabricated CAD-CAM allogeneic bone block sterilized hydrated using saline solution
Description: exposure of atrophic posterior mandibular ridge, augmentation with CAD-CAM prefabricated allogenic bone block which fixed with titanium screws. The block was coated with a nonporous d-PTFE membrane
Study NCT04833127 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gender-Enhanced -- Masibambane
Description: The intervention has components that provide PrEP information, provide information about HIV prevention and contraceptive options, prompt women to think about why they may be at risk for HIV, discuss women's sexual rights, and discuss how women can talk to their male partners about PrEP. The components are conducted by participants on their own time as well as during a real-time live interactive session with trained facilitators.
Study NCT04833127 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Individually accessed
Description: The intervention includes an individually-accessed online PrEP video and South African government websites on PrEP and on contraception options
Study NCT06634823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide Injectable Suspension
Description: Triamcinolone injection into deltoid muscle (arm)
Study NCT06634823 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline injection
Description: Saline injection into deltoid muscle (arm)
Study NCT05374200 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mind-body intervention with 1-1 support from study personnel
Description: The multicomponent intervention will consist of the following core components: (1) A choice between three different types of low-intensity, mindful movement videos - chair fitness, standing fitness, or standing tai chi (15-30 minutes/session); (2) Breathwork and theme-of-the-week based mindfulness meditations (5-10 minutes/session); (3) A once weekly positive psychology/behavior change activity presented as a point-and-click interactive storybook within the online site; (4) A once weekly disease management tip from a PBC physician.~Weekly brief (\~10-minute) motivational interview style telephone check-ins taking place during the intervention period will be conducted by a member of the study team. During these check-ins, progress will be reviewed, motivation provided, and questions answered.
Study NCT05113368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Oral regorafenib in a ReDOSplan (80 mg week#1, 120 mg week#2, 160 mg week#3 for cycle #1 then adjust final dose for subsequent cycles based on tolerance during cycle #1) \[3 weeks on/1 week off\] combined with intramuscular injection of fulvestrant 500 mg day #1 (day #15 will be planned only in cycle #1) in a 28-day cycle till disease progression or unacceptable toxicities
Study NCT05113368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500 mg day #1 (day #15 will be planned only in cycle #1) in a 28-day cycle till disease progression or unacceptable toxicities
Study NCT06436443 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SMS Counseling
Description: In addition to routine physician check-ups, an SMS group was created for the individuals in the intervention group, and basic information messages for diabetes control were sent to this group at regular intervals. In addition, individuals asked questions via this group. At the end of the eight-week follow-up, the data collection forms were filled out again and the study was terminated.
Study NCT05527652 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self-Supporting Nasopharyngeal Airway (ssNPA)
Description: The ssNPA device is made of a single piece of flexible, medical-grade silicone. It is inserted through one nostril and extends to the anatomic position bypassing the upper airway obstruction above the epiglottis.
Study NCT04538911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCG-PPD
Description: BCG-PPD was used for skin test in 30 TB patients, and BCG-PPD was marketed in other 30 TB patients (as control)
Study NCT04538911 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: BCG-PPD
Description: BCG-PPD was used for skin test in 30 TB patients, and BCG-PPD was marketed in other 30 TB patients (as control)
Study NCT05816304 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Digital Cognitive Behavioral Therapy for Insomnia (dCBTi)
Description: Digital CBTi is a computer-based cognitive behavioral therapy that provides strategies to improve sleep and daytime function (concentration, productivity) and decreases symptoms of sleep-related attributions, night-time thought content in individuals with insomnia. It is easily accessible with any internet-connected device, eg, computer, tabs, and smartphones.
Study NCT05755906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BFF MDI 160/9.6 μg BID (320/19.2μg/day)
Description: Budesonide/ Formoterol Fumarate (BFF) metered-dose inhaler (MDI), 160/9.6 μg BID (320/19.2μg/day)
Study NCT05755906 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BD MDI 160 μg BID (320 μg/day)
Description: Budesonide (BD) metered-dose inhaler (MDI), 160 μg BID (320 μg/day)
Study NCT05704868 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UniVRse + TAU
Description: UniVRse uses well-established evidence-basedcognitive behavioural therapy (CBT) techniques - specifically graded exposure - to reduce fear and worries about social situations. People work towards overcoming their anxiety in a step-by-step fashion, building up to the most feared situation. In the context of UniVRse, students will be presented with four university-based scenarios that our coproduction team identified as being the most anxiety-induing for students:~1. Attending a lecture;~2. Group work in a seminar;~3. Delivering a presentation;~4. Contributing to an online seminar.~The UniVRse programme has been designed with our co-production team comprised of tirst-generation students with social anxiety, CBT therapists, and a VR design company.
Study NCT04282174 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS
Description: allogeneic Human leukocyte antigen-compatible related or unrelated transplants of GCSF-mobilized peripheral blood stem cells depleted of T-cells by positive selection of CD34+ progenitor cells using the CliniMACS system
Study NCT04282174 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Transplant
Description: Bone Marrow Transplant will come from either an HLA matched related sibling or HLA un-related donor
Study NCT04282174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperfractionated Total Body Irradiation
Description: Hyperfractionated Total Body Irradiation is administered at a dose rate of \< 20 cGy/minute. Doses of 125 cGy/fraction are administered at a minimum interval of 4 hours between fractions, three times/day for a total of 11 or 12 doses (1375 or 1500 cGy) over 4 days (Day -9, -8, -7 and -6).
Study NCT04282174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Thiotepa: 5mg/kg/day IV over approximately 4 hr. daily x 2 (Day -5 and Day -4). If scheduling of transplant harvests requires, the dose of Thiotepa may be administered as a single dose of 10mg/kg/day x 1.
Study NCT04282174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide: 60 mg/kg/day I V over approximately 30 min daily x 2 days (d -3 and -2). Cyclophosphamide dosing will be adjusted if patient is > 125% of ideal body w eight and will be calculated based on adjusted ideal body weight, as per MCI standard of care guidelines.
Study NCT04282174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: 0.8 mg/kg every 6 hours x 10 or 12 doses), (depending on disease) with dose modified
Study NCT04282174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan 70mg/m2/day x 2 days IV over 30 minutes. Dose should be adjusted if patient is > 125% ideal body weight and should be calculated on adjusted ideal body weight per MCI standard of care guidelines. Melphalan will be administered on Days - 7 and -6 for multiple myeloma patients.
Study NCT04282174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25mg/m2/days x 5 days IV over 30 minutes. Fludarabine may be adjusted in the case of renal toxicity.~In select cases in which the peripheral blood stem cells must be harvested a day later than requested due to a scheduling issue with the donor or Stem Cell Processing Laboratory.
Study NCT05638282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cendakimab
Description: Specified dose on specified days
Study NCT05638282 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study NCT05455827 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI neurofeedback (A)
Description: Participants will be shown feedback about the BOLD activation within the subgenual anterior cingulate cortex to enhance differences between the self-blame and other-blame conditions
Study NCT05455827 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fMRI neurofeedback (B)
Description: Participants will be shown feedback about the BOLD activation within the subgenual anterior cingulate cortex to minimise differences between the self-blame and other-blame conditions
Study NCT05117853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autofluorescent detection + Injection of indocyanine green
Description: All four parathyroid glands will be actively sought for in every case selected for the use of AF/ICG, with AF verification of parathyroid tissue.~The timepoints of AF will be:~* 1 = after lateral dissection side 1 (side 1)~* 2= after lateral dissection side 2 (side 2)~The timepoints of ICG injection will be:~* 1 = after the first thyroid lobectomy (side 1)~* 2 = after the second thyroid lobectomy (side 2)~Scoring of the viability of parathyroid glands (adapted from Vidal Fortuny et al., 2016):~* 1 = black = not viable/vascularized~* 2 = grey = moderately viably/ moderately vascularized~* 3 = white = viable/well-vascularized
Study NCT05117853 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Gold standard of visual identification and evaluation of viability of the parathyroid glands.
Description: Gold standard of visual identification and evaluation of viability of the parathyroid glands.
Study NCT05493826 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Non-interventional study based on secondary use of hospital medical record
Study NCT05793021 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood sample
Description: Blood sample pre and post surgery to determine the level of FKBP51s protein
Study NCT06091293 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative Intervention for Long COVID-19 (NICO)
Description: The NICO intervention was delivered by a licensed psychotherapist asynchronously over a 3 month time period.
Study NCT04844645 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mini program
Description: To design, construct, and test the mini program in patients managing cancer pain